表紙:インドの免疫腫瘍薬市場 - 規模、シェア、見通し、および機会分析 2018年 - 2026年
市場調査レポート
商品コード
865102

インドの免疫腫瘍薬市場 - 規模、シェア、見通し、および機会分析 2018年 - 2026年

India Immune-Oncology Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2018- 2026

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 162 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=137.14円
インドの免疫腫瘍薬市場 - 規模、シェア、見通し、および機会分析 2018年 - 2026年
出版日: 2019年05月17日
発行: Coherent Market Insights
ページ情報: 英文 162 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートはインドの免疫腫瘍薬市場について調査し、市場の機会、成長および阻害要因、主な課題、医薬品の種類・癌の種類別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 調査の目的と仮定

  • 調査目的
  • 仮定
  • 略語

第2章 市場の概要

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 医薬品の種類別
    • 癌の種類別
  • COM (Coherent Opportunity Map)

第3章 市場力学、規制、および動向分析

  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 主な開発
  • 主な課題
  • 規制の状況
  • 患者の人口
  • 疫学分析
  • PEST分析
  • ポーターのファイブフォース分析

第4章 インドの免疫腫瘍薬市場:医薬品の種類別 2018年から2026年(100万米ドル)

  • イントロダクション
    • 市場シェア分析、2018年および2026年(%)
    • 成長分析 2018年~2026年
    • セグメント動向
  • 免疫チェックポイント阻害剤
    • イントロダクション
    • 市場規模と予測、および前年比成長率 2018年~2026年(100万米ドル)
    • ニボルマブ
    • アテゾリムマブ
    • ペンブロリズマブ
    • デュルバルマブ
  • モノクローナル抗体
    • イントロダクション
    • 市場規模と予測、および前年比成長率 2018年~2026年(100万米ドル)
    • リツキシマブ
    • トラスタズマブ
    • ベバシズマブ
    • ニモツズマブ
    • ペルツズマブ
    • アドトラスツズマブエムタンシン
  • 癌ワクチン
    • イントロダクション
    • 市場規模と予測、および前年比成長率 2018年~2026年(100万米ドル)
    • ガーダシル
    • サーバリックス

第5章 インドの免疫腫瘍薬市場:癌の種類別 2018年から2026年(100万米ドル)

  • イントロダクション
    • 市場シェア分析、2018年および2026年(%)
    • 成長分析 2018年~2026年
    • セグメント動向
  • 肺癌
    • イントロダクション
    • 市場規模と予測、および前年比成長率 2018年~2026年(100万米ドル)
  • 血液がん
  • 乳がん
  • 卵巣がん
  • 子宮頸癌
  • 大腸がん
  • 胃癌
  • 頭頸部がん
  • その他の癌

第6章 競合情勢

  • 企業プロファイル
    • Amgen, Inc.
    • F. Hoffmann-La Roche AG
    • Intas Pharmaceuticals Ltd.
    • AstraZeneca plc
    • Mylan N.V.
    • Dr. Reddy's Laboratories
    • Bristol-Myers Squibb
    • Merck & Co., Inc.
    • BIOCAD-Biotechnology company
    • Reliance Life Sciences
    • Biocon Limited
    • Hetero Drugs Limited
  • アナリストの意見

第7章 セクション

  • 参考文献
  • 調査方法
  • 当社と販売について
目次

Immuno-Oncology refers to the use of body's natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

Increasing prevalence of cancer in India is expected to drive India Immuno-Oncology Drugs market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

However, factors such as high-cost associated with immuno-oncology therapies makes it unaffordable for population in the low and middle-income class, to opt for these therapies, thus restraining growth of the market. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg. Moreover, according to the World Health Organization (WHO), in February 2018, around 70% of deaths from cancer occur in low and middle-income countries. This can be attributed to high-prices of oncology therapies, which cannot be afforded by patients with low incomes.

Key features of the study:

  • This report provides in-depth analysis of the India immuno-oncology drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the India immuno-oncology drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited and Hetero Drugs Limited.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • India immuno-oncology drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for India immuno-oncology drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

India Immuno-Oncology Drugs Market, By Drug Type:

  • Immune Checkpoint Inhibitors
    • Nivolumab (Opdivo)
    • Atezolimumab (Tecentriq)
    • Pembrolizumab (Keytruda)
    • Durvalumab (Imfinzi)
  • Monoclonal Antibodies
    • Rituximab (Rituxan)
    • Trastazumab (Herceptin)
    • Bevacizumab (Avastin)
    • Nimotuzumab (Biomab EGFR)
    • Pertuzumab (Perjeta)
    • Ado-Trastuzumab Emtansine (Kadcyla)
  • Cancer Vaccines
    • Gardasil
    • Cervarix

India Immuno-Oncology Drugs Market, By Cancer Type:

  • Lung Cancer
  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Stomach Cancer
  • Head & Neck Cancer
  • Others

Company Profiles

  • Amgen, Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • F. Hoffmann-La Roche AG
  • Intas Pharmaceuticals Ltd.
  • AstraZeneca plc
  • Mylan N.V.
  • Dr. Reddy's Laboratories
  • Bristol - Myers Squibb
  • Merck & Co., Inc.
  • BIOCAD-Biotechnology company
  • Reliance Life Sciences
  • Biocon Limited
  • Hetero Drugs Limited

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Cancer Type
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Key Challenges
  • Regulatory Landscape
  • Patient Population
  • Epidemiology Analysis
  • PEST Analysis
  • Porter's Five Forces model

4. India Immuno-Oncology Drugs Market, By Drug Type, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018 - 2026
    • Segment Trends
  • Immune Checkpoint Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Nivolumab
    • Atezolimumab
    • Pembrolizumab
    • Durvalumab
  • Monoclonal Antibodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Rituximab
    • Trastazumab
    • Bevacizumab
    • Nimotuzumab
    • Pertuzumab
    • Ado-Trastuzumab Emtansine
  • Cancer Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
    • Gardasil
    • Cervarix

5. India Immuno-Oncology Drugs Market, By Cancer Type, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018 - 2026
    • Segment Trends
  • Lung Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Blood Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Breast Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Ovarian Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Cervical Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Colorectal Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Stomach Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Head & Neck Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Other Cancers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

6. Competitive Landscape

  • Company Profiles
    • Amgen, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • F. Hoffmann-La Roche AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Intas Pharmaceuticals Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AstraZeneca plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Mylan N.V.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Dr. Reddy's Laboratories
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bristol-Myers Squibb
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • BIOCAD-Biotechnology company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Reliance Life Sciences
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Biocon Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Hetero Drugs Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

7. Section

  • References
  • Research Methodology
  • About Us and Sales Contact